A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)
{{output}}
Background: BAT2206 is being developed as a ustekinumab (UST) biosimilar. Objectives: Equivalent efficacy and comparable safety results of BAT2... ...
